An Investigator-initiated, multi-center, randomized controlled trial in HBR patients.
736 HBR patients (1:1 randomization) as per the ARC-HBR 2019 consensus definition.
Treatment arm – Supraflex Cruz (60 µm) sirolimus-eluting stent Comparative arm – Ultimaster Tansei (80 µm) sirolimus-eluting stent.
Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, MI, TVR, stroke and major bleeding events defined as per BARC 3 or 5 at 12 months.
According to the Guidelines of the European Society of Cardiology for Myocardial Revascularization 2019.
1 month, 6 months and 12 months post index PCI procedure.